SML0189

Indinavir sulfate salt hydrate

≥98% (HPLC), powder, antiretroviral agent

• Synonym(e): 2,3,5-Trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide sulfate hydrate, Crixivan hydrate, L-735,524 hydrate, MK-639 hydrate
• Empirische Formel (Hill-System): C₃₆H₄₇N₅O₄·H₂SO₄ · xH₂O
• Molekulargewicht: 711.87 (anhydrous basis)
• UNSPSC-Code: 51111800
• NACRES: NA.77

Eigenschaften

• product name: Indinavir sulfate salt hydrate, ≥98% (HPLC)
• Assay: ≥98% (HPLC)
• Form: powder
• Lagerbedingungen: desiccated
• Farbe: white to tan
• Löslichkeit: H₂O: ≥15 mg/mL
• Ersteller: Merck & Co., Inc., Kenilworth, NJ, U.S.
• Lagertemp.: 2-8°C

Beschreibung

Anwendung

Indinavir sulfate salt hydrate may be used in HIV-related cell signaling studies.

Biochem./physiol. Wirkung

Indinavir sulfate is an antiviral HIV protease inhibitor.

Indinavir sulfate suppresses the replication of HIV and is an important component of antiretroviral therapy for initial treatment of HIV infection. It is known to cause renal and urologic toxicity.

Leistungsmerkmale und Vorteile

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable